- Please check and comment entries here.
protein kinase AMP-activated non-catalytic subunit gamma 2
1. Normal Function
The PRKAG2 gene provides instructions for making one part (the gamma-2 subunit) of a larger enzyme called AMP-activated protein kinase (AMPK). This enzyme helps sense and respond to energy demands within cells. It is active in many different tissues, including heart (cardiac) muscle and muscles used for movement (skeletal muscles). AMP-activated protein kinase is likely involved in the development of the heart before birth, although its role in this process is unknown.
AMP-activated protein kinase regulates chemical pathways involving the cell's main energy source, a molecule called adenosine triphosphate (ATP). The breakdown of ATP releases energy to drive many types of chemical reactions. AMP-activated protein kinase is activated during times of cellular stress (such as low oxygen levels or muscle exercise), when ATP is broken down rapidly to produce energy. If ATP levels become too low, the enzyme restores the balance of energy by limiting chemical reactions that require ATP and stimulating pathways that generate ATP.
Studies suggest that AMP-activated protein kinase may play a role in controlling the activity of other genes, although many of these genes have not been identified. The enzyme may also regulate the activity of certain ion channels in the heart. These channels, which transport positively charged atoms (ions) into and out of heart muscle cells, play critical roles in maintaining the heart's normal rhythm.
2. Health Conditions Related to Genetic Changes
2.1. Wolff-Parkinson-White syndrome
At least seven mutations that cause Wolff-Parkinson-White syndrome have been identified in the PRKAG2 gene. Some people with these mutations also have features of hypertrophic cardiomyopathy, a form of heart disease that enlarges and weakens the heart (cardiac) muscle. Researchers are uncertain how PRKAG2 mutations lead to the development of these heart conditions. Research suggests that these mutations alter the activity of AMP-activated protein kinase in the heart, disrupting the enzyme's ability to respond to changes in cellular energy demands. It is unclear, however, whether the genetic changes overactivate the enzyme or reduce its activity.
Studies indicate that changes in AMP-activated protein kinase activity allow a complex sugar called glycogen to build up abnormally within cardiac muscle cells. The accumulation of this substance enlarges these cells, which may lead to hypertrophic cardiomyopathy. Researchers continue to investigate whether an abnormal buildup of glycogen in the heart is also responsible for the problems with electrical signaling that are characteristic of Wolff-Parkinson-White syndrome.
Other studies have found that altered AMP-activated protein kinase activity is related to changes in the regulation of certain ion channels in the heart. These changes may help explain the increased risk of abnormal heart rhythms (arrhythmias) in people with Wolff-Parkinson-White syndrome.
2.2. Other disorders
Several mutations in the PRKAG2 gene have been found in people with other heart conditions. For example, a specific mutation in this gene is responsible for a very severe form of heart disease called lethal congenital glycogen storage disease of the heart. People with this mutation are born with extremely enlarged hearts (cardiomegaly) and abnormal electrical signaling within the heart. These abnormalities lead to respiratory distress and heart failure early in life. The mutation responsible for this condition changes a single protein building block (amino acid) in the gamma-2 subunit of AMP-activated protein kinase. Specifically, this mutation replaces the amino acid arginine with the amino acid glutamine at position 531 (written as Arg531Gln or R531Q). Studies suggest that this severe disorder may be related to the abnormal buildup of glycogen within cardiac muscle cells.
Other mutations in the PRKAG2 gene have been associated with disorders affecting both cardiac and skeletal muscle. These mutations change single amino acids in the gamma-2 subunit of AMP-activated protein kinase. Individuals with these genetic changes typically experience muscle pain and stiffness, particularly following exercise, in addition to hypertrophic cardiomyopathy and abnormal electrical signaling within the heart. It is not known why the effects of some PRKAG2 mutations appear to be confined to the heart, while other mutations cause signs and symptoms affecting both cardiac and skeletal muscles.
3. Other Names for This Gene
AMP-activated protein kinase gamma2 subunit
protein kinase, AMP-activated, gamma 2 non-catalytic subunit
This entry is adapted from https://medlineplus.gov/genetics/gene/prkag2
- Ahmad F, Arad M, Musi N, He H, Wolf C, Branco D, Perez-Atayde AR, Stapleton D,Bali D, Xing Y, Tian R, Goodyear LJ, Berul CI, Ingwall JS, Seidman CE, SeidmanJG. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation. 2005 Nov 15;112(20):3140-8.
- Burwinkel B, Scott JW, Bührer C, van Landeghem FK, Cox GF, Wilson CJ, Grahame Hardie D, Kilimann MW. Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the gamma 2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency. Am J Hum Genet. 2005Jun;76(6):1034-49.
- Daniel T, Carling D. Functional analysis of mutations in the gamma 2 subunitof AMP-activated protein kinase associated with cardiac hypertrophy andWolff-Parkinson-White syndrome. J Biol Chem. 2002 Dec 27;277(52):51017-24.
- Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F,Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R. Identification of agene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001 Jun 14;344(24):1823-31. Erratum in: N Engl J Med 2001 Aug 16;345(7):552. HassanAS [corrected to Ali Hassan AS]. N Engl J Med 2002 Jan 24;346(4):300.
- Gollob MH, Green MS, Tang AS, Roberts R. PRKAG2 cardiac syndrome: familialventricular preexcitation, conduction system disease, and cardiac hypertrophy.Curr Opin Cardiol. 2002 May;17(3):229-34. Review.
- Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, RobertsR. Novel PRKAG2 mutation responsible for the genetic syndrome of ventricularpreexcitation and conduction system disease with childhood onset and absence ofcardiac hypertrophy. Circulation. 2001 Dec 18;104(25):3030-3.
- Hardie DG, Sakamoto K. AMPK: a key sensor of fuel and energy status inskeletal muscle. Physiology (Bethesda). 2006 Feb;21:48-60. Review.
- Laforêt P, Richard P, Said MA, Romero NB, Lacene E, Leroy JP, Baussan C,Hogrel JY, Lavergne T, Wahbi K, Hainque B, Duboc D. A new mutation in PRKAG2 genecausing hypertrophic cardiomyopathy with conduction system disease and muscularglycogenosis. Neuromuscul Disord. 2006 Mar;16(3):178-82.
- Murphy RT, Mogensen J, McGarry K, Bahl A, Evans A, Osman E, Syrris P, GormanG, Farrell M, Holton JL, Hanna MG, Hughes S, Elliott PM, Macrae CA, McKenna WJ.Adenosine monophosphate-activated protein kinase disease mimicks hypertrophiccardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am CollCardiol. 2005 Mar 15;45(6):922-30.
- Oliveira SM, Ehtisham J, Redwood CS, Ostman-Smith I, Blair EM, Watkins H.Mutation analysis of AMP-activated protein kinase subunits in inheritedcardiomyopathies: implications for kinase function and disease pathogenesis. JMol Cell Cardiol. 2003 Oct;35(10):1251-5.
- Sternick EB, Oliva A, Magalhães LP, Gerken LM, Hong K, Santana O, Brugada P,Brugada J, Brugada R. Familial pseudo-Wolff-Parkinson-White syndrome. JCardiovasc Electrophysiol. 2006 Jul;17(7):724-32.